BTIG sets Tempus stock Buy rating with $60 target

Published 21/04/2025, 11:54
BTIG sets Tempus stock Buy rating with $60 target

On Monday, BTIG initiated coverage on shares of Tempus AI Inc (NASDAQ:TEM), a technology firm specializing in precision medicine, with a Buy rating and a price target of $60. Currently trading at $40.45, the stock shows significant upside potential according to InvestingPro data, with analyst targets ranging from $48 to $74. Tempus AI, which is currently making strides in the oncology market, has been recognized for effectively monetizing its genomics and data business with medical oncologists and pharmaceutical companies.

The company’s ambition is to integrate generative artificial intelligence into diagnostics, aiding physicians and researchers in making more personalized, data-driven decisions to enhance patient care. With a market capitalization of $7 billion and impressive revenue growth of 30.4% in the last twelve months, Tempus AI has demonstrated strong market traction. While Tempus AI’s initial focus is on cancer, the company plans to expand its scale to other diseases, including cardiology.

Tempus AI boasts one of the world’s most extensive molecular libraries of cancer patient data. The goal is to become one of the few entities capable of effectively monetizing this resource. BTIG sees the company’s AI algorithms and data business as a potentially significant value proposition for investors. InvestingPro analysis reveals the company maintains a healthy current ratio of 2.29, indicating strong short-term financial stability.

The analyst from BTIG lauded Tempus AI for its early achievements in monetizing its services and sees the company’s generative AI as a key component in advancing personalized patient care. The firm’s extensive molecular library is expected to play a crucial role in its growth trajectory as it seeks to broaden its impact beyond oncology.

Tempus AI’s approach to leveraging artificial intelligence in healthcare has garnered attention for its potential to revolutionize how diseases are diagnosed and treated. With a strong start in the oncology sector, the company is poised to extend its innovative platform to other medical fields, aiming for widespread application of its technologies.

In other recent news, Tempus AI reported a 35.8% increase in revenue for the fourth quarter of 2024, reaching $700 million. Despite the robust revenue growth, the company posted a negative earnings per share (EPS) of -0.18. Tempus AI has also raised its 2025 revenue guidance to approximately $1.24 billion, which includes contributions from the recent acquisition of Ambry Genetics. The acquisition of Deep 6 AI is expected to enhance Tempus’s capabilities in supporting healthcare organizations with AI-driven research platforms. Analyst firm Stifel maintained a Hold rating on Tempus AI with a $65 price target, noting that the company’s valuation is in line with industry standards. Meanwhile, JPMorgan downgraded Tempus AI from Overweight to Neutral, although it raised the price target to $55, citing a slight revenue shortfall in non-core business areas. The company launched the Olivia AI personal health app, marking a strategic expansion into consumer health technology. These developments reflect Tempus AI’s ongoing efforts to expand its role in the healthcare technology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.